TD Cowen analyst Charles Rhyee lowered the firm’s price target on R1 RCM to $20 from $26 and keeps an Outperform rating on the shares. The firm said all the moving pieces for RCM has raised concerns over 2024 guidance with speculation that the company’s recent issues may drive 2024 adjusted EBITDA guide well below consensus current estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCM:
- R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business
- R1 RCM reports preliminary Q4 revenue $563M-$567M, consensus $586.58M
- R1 RCM price target lowered to $13 from $18 at KeyBanc
- Pediatrix Medical price target lowered to $10.50 from $12 at Truist
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
